article thumbnail

Rezvilutamide by Jiangsu Hengrui Medicine for Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100
article thumbnail

Rezvilutamide by Jiangsu Hengrui Medicine for Liver Failure (Hepatic Insufficiency): Likelihood of Approval

Pharmaceutical Technology

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). Rezvilutamide is indicated for the treatment of metastatic hormone sensitive prostate cancer. Rezvilutamide overview Rezvilutamide is an antineoplastic agent.

Medicine 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer triples sales forecast for prostate cancer drug Nubeqa

pharmaphorum

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours. The post Bayer triples sales forecast for prostate cancer drug Nubeqa appeared first on.

Sales 97
article thumbnail

Unblock My Hormones And Start Burning Fat TODAY With HB5

The Pharma Data

Product Name: Unblock My Hormones And Start Burning Fat TODAY With HB5. Click here to get Unblock My Hormones And Start Burning Fat TODAY With HB5 at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors.

article thumbnail

UK approves prescription-only melatonin drug for childhood ADHD

Pharmaceutical Technology

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Colonis Pharma’s melatonin oral solution for the treatment of sleep-onset insomnia in children and adolescents with attention-deficit hyperactivity disorder (ADHD). The hormone is produced endogenously in the body by the pineal gland.

Drugs 147
article thumbnail

Adalvo signs licence deal with EQL Pharma for Mellozzan

Pharmaceutical Technology

With a network of more than 134 local pharmaceutical companies, Adalvo supplies more than 110 different medicines in over 100 countries across the world. Mellozzan contains the sleep hormone melatonin and is indicated for use in children with attention deficit hyperactivity disorder (ADHD) and sleep difficulties.

Hormones 130
article thumbnail

Leading pharmaceutical compounding companies in contract marketing

Pharmaceutical Technology

The information contained within the download document is intended for pharmacists, pharmaceutical executives, sales managers, manufacturers, business development managers, pharmaceutical sales representatives, and any other individual involved in the pharmaceutical compounding sector. . • Test method development.

Marketing 130